Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ESH CLL 2022 | CLL treatment: a look into the future

John Allan • 16 Mar 2022

ESH CLL 2022

Chronic Lymphocytic Leukemia Leukemia

John Allan, MD, Weill Cornell Medicine, New York, NY, discusses the future of chronic lymphocytic leukemia (CLL) treatment, drawing focus on the excitement around moving towards fixed-duration, chemotherapy-free oral regimens and novel agents. Dr Allan also mentions the promise of Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors in the future of CLL treatment, and the importance of tailoring therapies based on a patient’s risk factors, comorbidities and disease biology. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.

Disclosures

(Consultancy: Abbvie, AstraZenenca, BeiGene, Genentech, Janssen, Pharmacyclics) Research Genentech, Janssen

Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax

John Allan • 12 Oct 2023

BruVenG trial: zanubrutinib and venetoclax, with obinutuzumab consolidation following MRD-positivity

John Allan • 12 Oct 2023

Combining BTK and BCL-2 inhibitors for the treatment of CLL

John Allan • 16 Mar 2022

Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation

John Allan • 16 Mar 2022

Related Videos

Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study

Alex Rampotas • 16 Apr 2024

Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias

Anthony Stein • 15 Apr 2024

Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies

Florent Malard • 11 Apr 2024

Investigating mutation order in AML using single-cell sequencing

Ravindra Majeti • 8 Apr 2024